Table 1. Association of hBD-1 expression in OSCC with patients' clinicopathological characteristics (n = 175).

	Total n	Negative n (percentage)	Weak n (percentage)	Strong n (percentage)	P value
Gender
Female	50	15 (30.0%)	24 (48.0%)	11(22.0%)	0.065
Male	125	58 (46.4%)	53 (42.4%)	14 (11.2%)
Age (year)
<60	85	38 (44.7%)	39 (45.9%)	8 (9.4%)	0.198
≥60	90	35 (38.9%)	38 (42.2%)	17 (18.9%)
Smoking status
Smoker	97	49 (50.5%)	38 (39.2%)	10 (10.3%)	0.029
Nonsmoker	78	24 (30.8%)	39 (50.0%)	15 (19.2%)
Differentiation
Well	107	29 (27.1%)	54 (50.5%)	24 (22.4%)	<0.001
Medium/Poor	68	44 (64.7%)	23 (33.8%)	1 (1.5%)
pT
T1–T2	90	35 (38.9%)	41 (45.5%)	14 (15.6%)	0.717
T3–T4	85	38 (44.7%)	36 (42.4%)	11 (12.9%)
pN
N0	110	39 (35.4%)	51 (46.4%)	20 (18.2%)	0.043
N1–Nx	65	34 (52.3%)	26 (40.0%)	5 (7.7%)
Tumor stage
I	17	5 (29.4%)	8 (47.1%)	4 (23.5%)	0.138
II	45	16 (35.5%)	21 (46.7%)	8 (17.8%)
III	46	21 (45.6%)	20 (43.5%)	5 (10.9%)
IV	67	31 (46.3%)	28 (41.8%)	8 (11.9%)